Predictive Biomarkers and Translational Cancer Medicine

2010 ◽  
pp. 87-117
Author(s):  
Anne-Sofie Schrohl ◽  
Pernille Hertel ◽  
Maj-Britt Jensen ◽  
Nils Bru_nner
Keyword(s):  
Predictive Biomarkers ◽  
Cancer Medicine

scholarly journals Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine

2021 ◽  
Vol Volume 14 ◽  
pp. 1517-1535
Author(s):  
Niamh Coleman ◽  
Justin T Moyers ◽  
Alice Harbery ◽  
Igor Vivanco ◽  
Timothy A Yap
Keyword(s):  
Predictive Biomarkers ◽  
Clinical Development ◽  
Patient Treatment ◽  
Cancer Medicine

Predictive Biomarkers and Translational Cancer Medicine

2019 ◽  
pp. 61-86
Author(s):  
Anne-Sofie Schrohl ◽  
Pernille Bræmer Hertel ◽  
Maj-Britt Jensen ◽  
Nils Brünner
Keyword(s):  
Predictive Biomarkers ◽  
Cancer Medicine

scholarly journals Harnessing Synthetic Lethal Interactions for Personalized Medicine

2022 ◽  
Vol 12 (1) ◽  
pp. 98
Author(s):  
Grace S. Shieh
Keyword(s):  
Synthetic Lethality ◽  
Predictive Biomarkers ◽  
Cancer Genes ◽  
Tumor Resistance ◽  
Future Directions ◽  
Synthetic Lethal ◽  
The Past ◽  
Synthetic Lethal Interactions ◽  
A Cell ◽  
Cancer Medicine

Two genes are said to have synthetic lethal (SL) interactions if the simultaneous mutations in a cell lead to lethality, but each individual mutation does not. Targeting SL partners of mutated cancer genes can kill cancer cells but leave normal cells intact. The applicability of translating this concept into clinics has been demonstrated by three drugs that have been approved by the FDA to target PARP for tumors bearing mutations in BRCA1/2. This article reviews applications of the SL concept to translational cancer medicine over the past five years. Topics are (1) exploiting the SL concept for drug combinations to circumvent tumor resistance, (2) using synthetic lethality to identify prognostic and predictive biomarkers, (3) applying SL interactions to stratify patients for targeted and immunotherapy, and (4) discussions on challenges and future directions.

Avenues to Precision Oncology

2020 ◽  
pp. 36-45
Author(s):  
Alexander Meisel
Keyword(s):  
Precision Medicine ◽  
Trial Design ◽  
Ad Hoc ◽  
Molecular Targets ◽  
Clinical Trial Design ◽  
Predictive Biomarkers ◽  
Precision Oncology ◽  
Companion Diagnostics ◽  
Bona Fide ◽  
The One

Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with ad hoc guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies significantly improved the clinical outcome of cancer patients. Nonetheless, such cutting-edge approaches revealed the limitation of the one-size-fits-all paradigm. The newly discovered molecular targets can be exploited either as bona fide targets for subsequent drug development, or as tools to precision medicine, in the form of prognostic and/or predictive biomarkers. This article provides an overview of some of the most recent advances in precision medicine in oncology, with a focus on novel tissue-agnostic anticancer therapies. The definition and implementation of biomarkers and companion diagnostics in clinical trials and clinical practice are also discussed, as well as the changing landscape in clinical trial design.

Sign in / Sign up

Export Citation Format

Share Document